The most expensive mistake in corporate innovation is a good-looking program that produces nothing.
We have a name for it. Innovation theater. It is when activity is optimized for visibility instead of outcomes. And it is far more common than anyone in the room is willing to admit.
After building 120+ ventures since 2013, the pattern is easy to recognize. A corporate launches an innovation program. The first 90 days fill up with workshops, strategy sessions, stakeholder alignment meetings, and a handful of polished presentations. Everyone feels productive. Calendars are full. Decks are circulating. Pilots are being “discussed.”
But conviction is not increasing. Uncertainty is not decreasing. No critical assumption has been tested, validated, or killed. The program is in motion, but it is not making progress.
What most teams miss is that activity alone does not reduce uncertainty. In the first phase of any venture program, the only thing that matters is whether you are making decisions — killing weak ideas, validating strong ones, narrowing the problem space. Everything else is noise.
Why theater is especially common in the GCC
This is especially pronounced in the GCC. Large corporates in Saudi Arabia and across the region face three reinforcing pressures that make theater almost inevitable: a cultural preference for visible effort, pressure to demonstrate engagement with national innovation agendas, and ambiguity about what “good progress” looks like in the first 90 days. These are not character flaws. They are structural conditions. And if you do not design against them deliberately, your innovation program will drift into performance mode without anyone noticing.
Six signals of innovation theater
Here are the signals to watch for. They tend to appear early, and they compound fast.
More presentations than experiments. If your team has produced more slide decks than tested assumptions by day 60, the ratio is wrong. Polished decks create the illusion of rigor. Evidence tables and assumption logs create the reality of it. Where this usually breaks is when leadership equates a well-structured presentation with a well-validated opportunity. They are not the same thing.
More events than evidence gates. Demo days, innovation showcases, and ecosystem tours are not inherently bad. But when they consume more calendar time than structured go/hold/stop decisions, you are optimizing for exposure rather than conviction. A demo day should exist to force a decision, not to impress a board.
More external hires than internal champions. Bringing in outside talent is sometimes necessary. But when the innovation team is entirely disconnected from the people who own P&L responsibility and operational knowledge inside the business, the program becomes a satellite. Satellites are easy to shut down. Internal champions with structural authority are not.
Budgets allocated without kill criteria. This is the clearest signal. If capital has been committed to an innovation program and there is no documented set of conditions under which that capital would be pulled back, you do not have a program. You have a sponsorship. Real programs have staged commitments with evidence gates at each stage. Every dollar deployed should come with a defined set of outcomes that would trigger a go, hold, or stop decision.
Artifacts becoming more polished over time. Deliverable quality is increasing but decision quality is flat. Teams start producing vision videos, branded playbooks, and polished decks because it feels like progress. It is not. Preferred artifacts in early-stage venture work are one-page summaries, evidence tables, and assumption logs. If a document takes longer to design than to write, question whether it is reducing uncertainty or just reducing anxiety.
Stops are rare or avoided. This might be the most diagnostic signal of all. In a well-run discovery phase, stopping an initiative is a successful outcome. It means you learned something, freed capacity, and avoided a larger mistake downstream. If everything in your portfolio “continues” and nothing gets explicitly killed, theater is already underway. Reframing stops as “pauses” is the most common way organizations disguise this problem from themselves.
Only 6% of executives say they are satisfied with their organization’s innovation results, even as global R&D spending exceeds $2.5 trillion. The constraint is not ideas or capital. It is alignment on what problems actually need solving. That alignment does not come from more workshops. It comes from forcing decisions early and often, even when the evidence is incomplete.
How to course-correct: Bold + Bounded
What we learned at TURN8 — and this took longer than it should have — is that the fix is to connect every activity to a specific decision. Before any workshop, interview, or research sprint begins, the team should be able to answer one question: what decision will this inform? If the answer is unclear, the activity should not proceed.
We call this Bold + Bounded. Take calculated risks, but with clear downside protection through staged commitments, evidence gates, and explicit go/hold/stop decisions. It is a philosophy of discipline. The boldness is in pursuing real problems aggressively. The boundary is in refusing to let activity substitute for evidence.
There is a simple diagnostic you can run right now. If two or more of the following are true, theater is likely present in your program: activity is increasing but decisions are not, artifacts are becoming more polished over time, stops are rare or avoided, and progress is hard to define precisely. If you recognize this pattern, reset scope immediately. Review which activities produced decisions in the last 30 days. Eliminate the ones that did not. Reinforce governance and validation discipline.
What kills corporate innovation more often than bad ideas is the absence of honest evaluation. The gap between what the program looks like from the outside and what it is actually producing on the inside. Theater fills that gap comfortably. Evidence gates do not. And if Phase One feels comfortable, it is probably not working.
The question worth sitting with is this: in the last 90 days of your innovation program, how many initiatives were explicitly stopped — and was that treated as a success or a failure?
Kamal Hassan is a Partner at TURN8, where he leads venture building and corporate venture capital programs across the GCC. TURN8 has built 120+ ventures and deployed $500M+ in capital since 2013.